Ryder System Inc: Form 10-Q for the period ended Sep 30, 2022
Filed with the SEC on Oct 26, 2022 and accepted by EDGAR at Oct 26, 2022, 14:59 ET.
Management's discussion and analysis
As filed, 3,854 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following table provides information with respect to purchases we made of our common stock during the three months ended September 30, 2022:
(Dollars in thousands, except per share)
| Total Number of Shares Purchased (1) | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Programs | Maximum Number of Shares That May Yet Be Purchased Under the Discretionary and Anti-Dilutive Programs (2) | Maximum Number of Dollars That May Yet Be Purchased Under the Accelerated Share Repurchase Program (3) | |
|---|---|---|---|---|---|
| July 1 through July 31, 2022 | 23 | $75.10 | — | 4,500,000 | $65,272 |
| August 1 through August 31, 2022 | — | — | — | 4,500,000 | $65,272 |
| September 1 through September 30, 2022 | 976,130 | 67.98 | 975,960 | 4,500,000 | $— |
| Total | 976,153 | $67.98 | 975,960 |
(1) During the three months ended September 30, 2022, we purchased an aggregate of 193 shares of our common stock in employee-related transactions. Employee-related transactions may include: (i) shares of common stock withheld as payment for the exercise price of options exercised or to satisfy the tax withholding liability associated with our share-based compensation programs and (ii) open-market purchases by the trustee of Ryder’s deferred compensation plans relating to investments by employees in our stock, one of the investment options available under the plans.
(2) In October 2021, our board of directors authorized two new share repurchase programs. The first program grants management discretion to repurchase up to 2.0 million shares of common stock over a period of two years, commencing on October 14, 2021 and expiring on October 14, 2023 (the "2021 Discretionary Program"). The 2021 Discretionary Program is designed to provide management with capital structure flexibility while concurrently managing objectives related to balance sheet leverage, acquisition opportunities, and shareholder returns. The second program authorizes management to repurchase up to 2.5 million shares of common stock, issued to employees under the company's employee stock plans since September 1, 2021 (the "2021 Anti-Dilutive Program"). The 2021 Anti-Dilutive Program is designed to mitigate the dilutive impact of shares issued under the company's employee stock plans. The 2021 Anti-Dilutive Repurchase Program commenced on October 14, 2021 and expires on October 14, 2023. Share repurchases under both programs can be made from time to time using the company's working capital and a variety of methods, including open-market transactions and trading plans established pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934. The timing and actual number of shares repurchased are subject to market conditions, legal requirements and other factors, including balance sheet leverage, availability of quality acquisitions and stock price.
(3) In September 2022, we completed our $300 million accelerated share repurchase program. This program was authorized by our board of directors in February 2022, and at that time, we repurchased and retired an initial share amount of approximately 3 million. The final settlement occurred in September 2022, resulting in the delivery and retirement of approximately 1 million additional shares. The number of shares ultimately repurchased and retired was based on the average of Ryder's daily volume-weighted average price per share of common stock during a repurchase period, less a discount. The average price paid for all of the shares delivered and retired under the ASR was $74.47 per share. Refer to Note 11, "Share Repurchase Programs," in the Notes to Condensed Consolidated Financial Statements for a discussion on our share repurchase programs.
Market risk
As filed, 213 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes to Ryder’s exposures to market risks since December 31, 2021. Please refer to the 2021 Annual Report on Form 10-K for a complete discussion of Ryder’s exposures to market risks.
Controls and procedures
As filed, 1,009 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
As of the end of the third quarter of 2022, we carried out an evaluation, under the supervision and with the participation of management, including Ryder’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of Ryder’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that as of the end of the third quarter of 2022, Ryder’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934) were effective.
Changes in Internal Control over Financial Reporting
During the nine months ended September 30, 2022, there were no changes in Ryder's internal control over financial reporting that have materially affected or are reasonably likely to materially affect such internal control over financial reporting.
Risk factors
As filed, 510 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
To our knowledge and except to the extent additional factual information disclosed in this Quarterly Report on Form 10-Q relates to such risk factors, there have been no material changes in the risk factors described in "Item 1A. Risk Factors" in our Form 10-K for the year ended December 31, 2021, filed with the SEC on February 17, 2022. Our operations could also be affected by additional risk factors that are not presently known to us or by factors that we currently consider not material to our business.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-07-01 to 2022-09-30 | $3.04bn | us-gaap:Revenues |
| Revenue | 9 months2022-01-01 to 2022-09-30 | $8.92bn | us-gaap:Revenues |
| Selling, general and administrative | 3 months2022-07-01 to 2022-09-30 | $349.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2022-01-01 to 2022-09-30 | $1.05bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months2022-07-01 to 2022-09-30 | $57.8m | us-gaap:InterestExpense |
| Interest expense | 9 months2022-01-01 to 2022-09-30 | $165.5m | us-gaap:InterestExpense |
| Income tax | 3 months2022-07-01 to 2022-09-30 | $87.8m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-01-01 to 2022-09-30 | $261.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-07-01 to 2022-09-30 | $246.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-01-01 to 2022-09-30 | $661.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-07-01 to 2022-09-30 | $4.82 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-01-01 to 2022-09-30 | $12.82 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-07-01 to 2022-09-30 | $4.91 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-01-01 to 2022-09-30 | $13.09 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-07-01 to 2022-09-30 | 51,073,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-01-01 to 2022-09-30 | 51,278,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-01-01 to 2022-09-30 | $1.79bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2022-07-01 to 2022-09-30 | $721.7m | us-gaap:PaymentsToAcquireProductiveAssets |
| Capital expenditure | 9 months2022-01-01 to 2022-09-30 | $1.92bn | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 9 months2022-01-01 to 2022-09-30 | $93.9m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months2022-01-01 to 2022-09-30 | $300.3m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-09-30 | $456.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-09-30 | $2.34bn | us-gaap:AssetsCurrent |
| Total assets | At period end2022-09-30 | $14.50bn | us-gaap:Assets |
| Current liabilities | At period end2022-09-30 | $3.20bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-09-30 | $11.49bn | us-gaap:Liabilities |
| Current portion of debt | At period end2022-09-30 | $1.05bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2022-09-30 | $3.01bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2022-09-30 | 50,251,092 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000085961-22-000166. Last ingested by Listed: Oct 29, 2026, 09:46 ET. Listed shows no prices and gives no investment advice.